Deciphera Pharmaceuticals to Host Virtual Investor Event Featuring Key Opinion Leaders to Discuss Rebastinib and Vimseltinib Data Presented at ESMO Congress 2021

Deciphera Pharmaceuticals (NASDAQ: DCPH) will host a virtual investor event on September 17, 2021, from 10:00 AM to 12:30 PM ET, to discuss clinical data for rebastinib and vimseltinib ahead of the ESMO Congress 2021.

Rhea-AI Impact

(Neutral)

Rhea-AI Sentiment

(Neutral)

Tags

conferences

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

09/10/2021 - 07:00 AM

WALTHAM, Mass.--(BUSINESS WIRE)-- Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that the Company will host a virtual investor event to review the rebastinib and vimseltinib clinical data to be presented at the upcoming European Society for Medical Oncology (ESMO) Congress 2021 on Friday, September 17, 2021, from 10:00 AM to 12:30 PM ET.

Deciphera’s senior executive team will be joined by the following key opinion leaders at the event:

Dr. Robert L. Coleman, M.D., FACOG, FACS, Gynecologic Oncologist and Chief Scientific Officer at US Oncology Research
William D. Tap, M.D., Chief of the Sarcoma Medical Oncology Service at Memorial Sloan Kettering Cancer Center

A live webcast of the event may be accessed through the “Investors” section of Deciphera’s website at www.deciphera.com. A replay of the webcast will be available following the event.

About Deciphera Pharmaceuticals

Deciphera is a biopharmaceutical company focused on discovering, developing and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, QINLOCK^® is Deciphera’s FDA-approved switch-control kinase inhibitor for the treatment of fourth-line gastrointestinal stromal tumor (GIST). QINLOCK is also approved for fourth-line GIST in Australia, Canada, China, Hong Kong, and Taiwan. For more information, visit www.deciphera.com and follow us on LinkedIn and Twitter (@Deciphera).